BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1858 related articles for article (PubMed ID: 29726071)

  • 21. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
    Hofman MS; Iravani A
    PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
    Arsenault F; Beauregard JM; Pouliot F
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
    Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
    [No Abstract]   [Full Text] [Related]  

  • 26. Advances in prostate-specific membrane antigen PET of prostate cancer.
    Bouchelouche K; Choyke PL
    Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment outcomes of metastasis-directed treatment using
    Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
    Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography on the Therapeutic Decision of Prostate Carcinoma Primary Staging: A Retrospective Analysis at the Brazilian National Public Health System.
    da Silva ACB; de Toledo LGM; de Carvalho Fernandes R; Ziroldo AR; Sawczyn GV; Alarcon ST; Lewin F
    Ann Surg Oncol; 2023 Jul; 30(7):4541-4549. PubMed ID: 36995451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
    Kim SJ; Lee SW; Ha HK
    Urol Int; 2019; 102(1):27-36. PubMed ID: 30269140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
    Ravi Kumar AS; Lawrentschuk N; Hofman MS
    Curr Opin Urol; 2020 Sep; 30(5):628-634. PubMed ID: 32701720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
    Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
    Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
    Hinsenveld FJ; Wit EMK; van Leeuwen PJ; Brouwer OR; Donswijk ML; Tillier CN; Vegt E; van Muilekom E; van Oosterom MN; van Leeuwen FWB; van der Poel HG
    J Nucl Med; 2020 Apr; 61(4):540-545. PubMed ID: 31562222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
    McEwan L; McBean R; Yaxley J; Wong D
    J Med Imaging Radiat Oncol; 2019 Jun; 63(3):318-323. PubMed ID: 30840361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer.
    Donswijk ML; Ettema RH; Meijer D; Wondergem M; Cheung Z; Bekers EM; van Leeuwen PJ; van den Bergh RCN; van der Poel HG; Vis AN; Oprea-Lager DE
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1741-1752. PubMed ID: 38273003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic accuracy of
    Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
    Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
    van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
    BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
    Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential Impact of
    Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
    J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 93.